IPO News | Jia Yin Biotechnology Files Again for Hong Kong Stock Exchange
According to the Hong Kong Stock Exchange's disclosure on August 28, Exegenesis Bio Inc. (referred to as: ) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with CICC acting as its sole sponsor.
According to the Hong Kong Stock Exchange's disclosure on August 28, Exegenesis Bio Inc. (referred to as: ) has submitted a listing application to the main board of the Stock Exchange, with CCB International as its exclusive sponsor. The prospectus reveals that is a biopharmaceutical company focused on the discovery and development of gene therapies for neurological and ophthalmic diseases. The company's pipeline also includes oligonucleotide therapies. Established in 2019, the company has built a pipeline of nine candidate products through its fully integrated in-house R&D platform. Through this platform, the company has internally developed two core products (EXG102-031 and EXG001-307 (SMA Type 1)) and one key product (EXG202).
Related Articles
HK Stock Market Move |
Huachuang Securities: Small and medium-sized brokerages still possess cyclical elasticity, and product capability determines development space.
HK Stock Market Move | Shenzhen Longsys Electronics (09976) rose over 7% in early trading, with a net profit exceeding 10 billion in the first half of the year. The company is a leading domestic memory module manufacturer.
HK Stock Market Move |
Huachuang Securities: Small and medium-sized brokerages still possess cyclical elasticity, and product capability determines development space.
HK Stock Market Move | Shenzhen Longsys Electronics (09976) rose over 7% in early trading, with a net profit exceeding 10 billion in the first half of the year. The company is a leading domestic memory module manufacturer.
RECOMMEND
